Bienville Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Bienville Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$213K	Hold	58,053	–	–	0.03%	92
2026 Q1	$178K	Hold	58,053	–	–	0.03%	72
2025 Q4	$237K	Hold	58,053	–	–	0.04%	71
2025 Q3	$283K	Hold	58,053	–	–	0.05%	64
2025 Q2	$294K	Hold	58,053	–	–	0.06%	60
2025 Q1	$307K	Hold	58,053	–	–	0.07%	57
2024 Q4	$392K	Hold	58,053	–	–	0.1%	66
2024 Q3	$383K	Hold	58,053	–	–	0.1%	64
2024 Q2	$435K	Hold	58,053	–	–	0.1%	61
2024 Q1	$579K	Hold	58,053	–	–	0.18%	55
2023 Q4	$572K	Hold	58,053	–	–	0.16%	61
2023 Q3	$444K	Buy	58,053 +1,177	+2%	+$11.7K	0.12%	64
2023 Q2	$425K	Hold	56,876	–	–	0.14%	61
2023 Q1	$379K	Hold	56,876	–	–	0.14%	69
2022 Q4	$439K	Sell	56,876 -4,062	-7%	-$39.8K	0.13%	61
2022 Q3	$648K	Buy	60,938 +24,375	+67%	+$247K	0.25%	50
2022 Q2	$298K	Hold	36,563	–	–	0.14%	103
2022 Q1	$262K	Hold	36,563	–	–	0.13%	120
2021 Q4	$626K	Buy	+36,563	New	+$688K	0.45%	44

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bienville Capital Management's RXRX Position: Q2 2026 in Review

Bienville Capital Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 58,053 shares worth $213K. The position accounts for 0.03% of the portfolio, ranked #92.

Bienville Capital Management first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $648K in Q3 2022. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Bienville Capital Management held 58,053 shares of Recursion Pharmaceuticals worth $213K as of Q2 2026.
Bienville Capital Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up 0.03% of Bienville Capital Management's portfolio in Q2 2026, its #92 holding.
Bienville Capital Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Bienville Capital Management's Recursion Pharmaceuticals position peaked at $648K in Q3 2022.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Bienville Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.